Spending on hepatitis C treatments, including options from Gilead Sciences and AbbVie, increased 734 percent from 2013 to 2014.
Spending on specialty drugs, including treatments for conditions such as HCV, cancer and multiple sclerosis, accounted for 31 percent of drug spending last year, according to the report.
More articles on gastroenterology:
FDA advisory panel to discuss ‘superbug’ infections
3 MUSE procedures for GERD performed in Italy
Loyola University Health System adds Dr. Lesley Rhee
